Akari Therapeutics (AKTX) Research & Development (2014 - 2026)

Akari Therapeutics has disclosed Research & Development across 9 years of filings, most recently posting $1.5 million for Q1 2026.

• Research & Development for Q1 2026 came in at $1.5 million, up 79.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.5 million (down 69.9% YoY), and the FY2025 annual result was $2.8 million, down 59.69% from the prior year.
• Research & Development came in at $1.5 million for Q1 2026 at Akari Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $7.2 million in Q4 2024 to a low of -$314000.0 in Q3 2023.
• The 4-year median for Research & Development is $1.5 million (2026), against an average of $1.7 million.
• Across the five-year window, Research & Development jumped 188.16% in 2024 and tumbled 84.98% in 2025, its largest moves.
• Akari Therapeutics' Research & Development stood at $2.5 million in 2023, then surged by 188.16% to $7.2 million in 2024, then sank by 84.98% to $1.1 million in 2025, then surged by 34.35% to $1.5 million in 2026.
• The last three Research & Development figures came in at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $249000.0 (Q3 2025), per Business Quant data.